Research Institutes That Provided Data for Sharp s

Research Institutes That Provided Data For Sharp S-Free PDF

  • Date:26 Oct 2020
  • Views:2
  • Downloads:0
  • Pages:128
  • Size:7.07 MB

Share Pdf : Research Institutes That Provided Data For Sharp S

Download and Preview : Research Institutes That Provided Data For Sharp S


Report CopyRight/DMCA Form For : Research Institutes That Provided Data For Sharp S


Transcription:

SEAL OF APPROVAL,CERTIFICATE,This is to certify that. Sharp Electronics UK Ltd,Has been awarded the British Allergy Foundation. Seal of Approval for reduction in exposure to House Dust Mite and Pollen for their product. Plasmacluster Air Purifier,Model No s without Humidifying Function Countries. KC930EK UK,FUW53E FUW43E FUW28E FPF30EU FUY30EU EU Russia. FPP30U FPA80U FPA60U FPA40U FPA40C FPA28U FPA28C FPF60U FPF50U North America. FUA80SA FUA80EA FUY30EU FUZ31E FUY30SA Middle East. FUW53J FUW28J FUA80J FPF30J FPG50J FUY30J Australia. New Zealand, FUZ35TA FUY50K FUA80E FUA80A FUA80TA FUA80T FUA80Y FUW50A Asia.
FUW40A FUW25A FUW53E FUW53TA FUW43E FUW43TA FUW43T FUD40T. FPD40T FUD40A FPD40A FUD50A FPD50TA FPD50E FPD50Y FUD80T FUD50T. FUE30A FPE50E FPE50TA FPE50Y FU551KB FU551KY FU551KE FU551KT FPF30L. FPF30E FPF30TA FPF30Y FPF30SA FPF30A FPF40L FPF40E FPF40TA FPF40Y FPF40A. FP FM40L FPFM40E FPFM40B FPFM40Y FPGM30E FPGM30L FPGM30Y FPGM30B. FPG50L FPG50E FPG50TA FPG50Y FPGM50L FPGM50E FPGM50B FPGM50Y. DWE16FA FPAG9 FPJ30E FPJ30L FPJ30TA FPJ30Y FPJ30M FU GM50T FU G30T. FP FM40A FUHM30T FUH30T FUG50T FPHM30A FPH50A FUJH70T FPH80L. FPH80E FPH80TA FUY30E FUY30A FUY30K FUY30TA FUY30T FUY30EV FUZ31E. FUZ31Y FUZ31T FUY28E FUY28TA FUY28Y FUY28EP FUA28E FUA28TA FUA28Y. FUA28EV FUD30T FPJ30K FP H30A B FP J40K FU H80T FP H90L. FUA420S FUAW240SR FUAW240SW FUCD30 FUWD30 FUBD30 FUCD20 FUWD20 China. FUBD20 FUWE10 FUBE10 FUCE10 FUBE80 FXCF100 FXCF90 FUBF30 FUGFM50. DWCE15F DWE10FT FXCG908 FUBF30W1 FPBG500W FUBG31 FPCH70 FUY180SW. FUGB10 FP WH70 FU WGM51, FUA80 FUA51 FUB51 FU D80 FU D51 CV DF100 FUE80 FUE51 CV EF120 FUF51 Japan. FUGK50 FP140EX FPFX2 FUG51 FUH50 FPAT3 FUA30 FU30P1 FUB30 FU D30. FUE30 FUF30 FUF28 FUG30 FUH30 FU JK50, Appropriate Room Sizes and the following wording must be Clearly Marked on External Packaging and Instruction Manual. Carla Jones Chief Executive,Licence No 323,Valid until 8th August 2019. Allergy UK is the operational name of The British Allergy Foundation a charitable company limited by guarantee and registered in. England and Wales Company No 4509293 Charity No 1094231. Registered in Scotland Charity No SC039257,September 18 2014. In an investigator initiated 1 clinical trial Plasmacluster Ion technology 2. reduced airway inflammation in pediatric patients with mild 3 to. moderate 4 atopic asthma, In investigator initiated clinical research 5 commissioned by Sharp results were obtained in.
exploratory analysis 6 indicating that Plasmacluster Ion technology reduced the level of. airway inflammation in pediatric patients with mild to moderate atopic asthma FeNO 7. value less than 90, Sharp commissioned The University of Tokyo Hospital Clinical Research Support Center. to conduct this research and provided special Plasmacluster Ion generators for use in the. clinical study Mr Yasuo Ohashi Emeritus Professor of The University of Tokyo and also a. Professor on the Faculty of Science and Engineering at Chuo University assumed. responsibility for data analysis and design of the clinical research In addition Mr Toshio. Katsunuma Associate Professor Department of Pediatrics The Jikei University Daisan. Hospital served as coordinator of trial sites and was in charge of recruiting subjects as well. as testing and measurement, This clinical study targeted 130 pediatric patients with mild to moderate atopic asthma In. this clinical research study special Plasmacluster Ion generators producing an ion. concentration of 100 000 ions cm3 were set up in the home in two rooms where the. subjects spent long periods of time selected from among the bedroom living room and. children s room nursery Observations were made for eight weeks before and eight weeks. after activation of the Plasmacluster Ion generators using the individual randomized. crossover double blind comparison protocol 8, This clinical study found that the level of airway inflammation in children with atopic asthma. was reduced and that Plasmacluster Ion technology 2 will contribute to human health in an. actual living environment,Press Release No 14 009, Dust mite allergens are one of the major antigens causing asthma Thus far Sharp has. proven that Plasmacluster Ions have an inhibitory effect against airborne dust mite. allergens 9 which are in dust mite fecal pellets and body fragments and also went on to. elucidate the mechanism underlying the inhibition of these allergens 10. In the future Sharp will push ahead with further development of Plasmacluster Ion. technology 2 and continue to prove its efficacy with the aim of creating a healthy. environment, It should also be noted that the details of this clinical study are scheduled to be presented.
by the research group Professors Yasuo Ohashi and Toshio Katsunuma at the 51 st Annual. Meeting of the Japanese Society of Pediatric Allergy and Clinical Immunology to be held. beginning November 8 2014, Comments by Mr Yasuo Ohashi Emeritus Professor of The University of Tokyo and. Professor Faculty of Science and Engineering Chuo University. This double blind randomized clinical study of a home appliance technology for pediatric. asthma patients is unique and I can say that there is a strong trailblazing spirit in this. current study The findings indicate that there is a potential for Plasmacluster Ion. technology to reduce the level of airway inflammation in pediatric patients with mild or. moderate atopic asthma This study will contribute to the development and deployment of. the methodology and I think it suggests that Plasmacluster Ion technology will make a. difference in the world, Comments of Mr Toshio Katsunuma Associate Professor Department of Pediatrics. The Jikei University Daisan Hospital, Plasmacluster Ion technology is not a drug nor even medical equipment This technology. shows the potential to suppress respiratory tract inflammation in children with mild to. moderate asthma and to improve their respiratory function and I think this is highly. significant with respect to undertaking long term care of asthmatic children. It is my hope that this data will bring good news to children with asthma and to their. 1 The University of Tokyo Hospital Clinical Research Support Center was commissioned to conduct this. research and provide research support, 2 Plasmacluster is a registered trademark of Sharp Corporation. 3 Mild asthma is defined as having coughing or wheezing symptoms more than once a month but not. more than once a week At times it may be accompanied by difficulty in breathing Duration is short and. interference in daily life is minimal based on the Japanese Pediatric Guideline for the Treatment and. Management of Asthma 2012, 4 Moderate asthma is defined as having coughing or wheezing symptoms at least once week but not.
continuing on a daily basis On occasion it may manifest as a moderate to severe attack and disrupts. sleep and or normal daily activities based on the Pediatric Guideline for the Treatment and. Management of Asthma 2012, 5 The University of Tokyo Hospital Clinical Research Support Center the organization contracted to. conduct this research is independent of Sharp Corporation and was commissioned to provide support in. the form of planning of clinical research to implementation and reporting. 6 Prior to the start of the study it was determined that the analysis would cover all subjects However. under this criteria it was not possible to verify the effects of Plasmacluster Ion technology most likely. because subjects suffering from high levels of inflammation were included By limiting the range of. subjects an improvement in respiratory function was found for which expectations were initially low. 7 Fractional exhaled nitric oxide a measure of the concentration of NO in exhaled breath An indicator of. the level of airway inflammation, 8 A protocol for clinical trials designed to objectively examine the efficacy of investigational new drugs. 9 Announced on September 3 2003,10 Announced on July 21 2006. Overview of Clinical Research,Participants, 130 asthma patients between the ages of 6 and 15 years with mild 3 or moderate 4 cases. Research design, Subjects were randomly split into two groups and ion generators made specifically for.
clinical research were placed in their homes, The individually randomized double blind crossover comparison protocol 8 was used. August 9 2013 to May 30 2014,Assessment items, Change in FeNO value 7 change in asthma symptoms change in respiratory function. value QOL quality of life 11, Ion density of ion generating device made specifically for clinical research. Maximum ion density of approximately 100 000 ions cm3. Test results, For subjects who had an initial FeNO value 7 of 90 or less compared to the placebo. device 12 use of the ion generating device made specifically for clinical research resulted in. a decrease an improvement in the FeNO value 7 which is one of the indicators of. inflammation, For subjects who had an initial FeNO value 7 of 90 or less compared to the placebo.
device 12 use of the ion generating device made specifically for clinical research resulted in. an increase an improvement in V25 13 which is one of the indicators showing constriction. of peripheral airways of lungs, Compared to pre test values by the end of the test there was a decrease an. improvement in the QOL score, 11 QOL Like the name suggests Quality of Life is an assessment of the quality of a person s day to day. living conditions, 12 Placebo device A device that disperses air without Plasmacluster Ions. 13 An indicator of the state of the airways in particular the peripheral airways of lungs one of the factors of. respiratory functions,Sharp Corporation, HQ 1 Takumi cho Sakai ku Sakai shi Osaka fu 590 8522. URL http www sharp co jp,September 8 2016, Plasmacluster Technology1 Proven to Decrease Risk of Tuberculosis.
Infection in Tuberculosis Hospital for the First Time2. Sharp in cooperation with WHO Global Health Workforce Alliance3 National Center of Tuberculosis and Lung. Disease in Tbilisi Georgia has effectively proven the decreased risk of Tuberculosis transmission among hospital. healthcare workers and prevention of acquired drug resistance ADR 4 among patients using Plasmacluster. technology 100 000 ions cm3 for the first time in history. Tuberculosis is an infection caused by bacteria Mycobacterium Tuberculosis Over 9 6 million people worldwide. were infected with Tuberculosis5 in 2015 and 1 5 million of those died from the disease5 This makes it one of the. most fatal stand alone infection in the world, By releasing Plasmacluster positive ions H H2O m and negative ions O2 H2O n in the air at the same. time Plasmacluster ions form highly oxidized OH radicals that break down the surface protein of airborne microbes. leading to their complete eradication In cooperation with Chest Disease Institute Dr Charoen of Thailand. Plasmacluster technology was used to effectively suppress attached Tuberculosis bacteria Those findings were. released in September 20096 This time Plasmacluster ion test devices emitting an average ion concentration of. 100 000 ions cm3 were set up at Tuberculosis hospital Through this test the decreased risk of Tuberculosis. infection for healthcare workers and positive impact in preventing the development of acquired drug resistance for. Tuberculosis patients were confirmed, Sharp has been involved with academic marketing7 to verify the effectiveness of Plasmacluster technology in. cooperation with global testing organizations since 2000 The effectiveness of controlling hazardous substances. such as new types of the influenza virus drug resistant bacteria mite allergens and also reducing the risk of. tracheal inflammation in childhood asthma patients8 has been proven in our 28 tests that took place so far9 The. safety of Plasmacluster technology has also been confirmed10 through these trials Sharp aims to continue such. types of studies to explore even more benefits that the Plasmacluster technology can support the society with. It should also be noted that the details of this clinical study are scheduled to be presented by the research group at. the 21st Congress of Asian Pacific Society of Respirology to be held on November 12 15 2016. Comment from the National Center of Tuberculosis and Lung Disease in Tbilisi Georgia. Until now there have been limited data globally from high TB burden settings on how Infection Control means. such as ventilation UV etc contribute to the prevention of Tuberculosis transmission within hospitals With the. current research on Plasmacluster technology we have been able to accomplish this task and developed capacity. that can be used to pioneer future scientific experiments in the field We believe Plasmacluster technology has a. good chance to play an important role as one of the measures to prevent the spread of Tuberculosis bacteria in. specialized Tuberculosis hospitals, 1 Plasmacluster is a trademark of Sharp Corporation. 2 Test applicable to healthcare providers and tuberculosis patients using engineering control in tuberculosis. hospitals Sep 8 2016 Sharp research, 3 WHO HP http www who int workforcealliance members partners member list tbgeo en. 4 Acquired drug resistance ADR is defined as patients that develop resistance to antituberculosis drugs. 5 World Health Organization Tuberculosis fact sheet number 104 Reviewed March 2016. Appropriate Room Sizes and the following wording must be Clearly Marked on External Packaging and Instruction Manual Signed Carla Jones Chief Executive Licence No 323 Valid until 8th August 2019 Allergy UK is the operational name of The British Allergy Foundation a charitable company limited by guarantee and registered in England and Wales Company No 4509293 Charity No 1094231

Related Books